Innovating Works

SOPHIA

Financiado
Stratification of Obesity Phenotypes to Optimize Future Therapy
SOPHIA will optimise the future treatment of obesity. The challenge is that clinicians, payers and patients view obesity as a failure of self-control, rather than a disease. We will change this perspective by defining subpopulatio... SOPHIA will optimise the future treatment of obesity. The challenge is that clinicians, payers and patients view obesity as a failure of self-control, rather than a disease. We will change this perspective by defining subpopulations in terms of (a) the risks of complications linked to obesity, (b) response to various obesity treatments. The subpopulations will be characterised in terms of operational variables (phenotypic, genetic, behavioural, environmental, and omics). These predictive variables will facilitate diagnosis and underpin personalised and protocolised obesity care. Patient priorities regarding risk and response will influence all aspects of our work. SOPHIA will create a federated database of premier EU cohorts to identify operational variables that are predictive of risk and treatment response in people with and without diabetes. We will validate the predictive value of these variables before creating clinically-useful algorithms to decide when-to-treat and how-to-treat. Biomarker variables will feed into innovative assays, tests and research targets. We will interpret and analyse our results, to identify shared value across all stakeholders (patients, clinicians, industry, payers). SOPHIA will change attitudes and experience of obesity by (1) demonstrating the heterogeneity of the disease, (2) identifying people at risk of complications, (3) identifying the best treatment for each individual, (4) delivering a common vocabulary and shared understanding of obesity, (5) demonstrating shared value, which combines commercial opportunity with societal benefit. Our ambition will only be realised if (a) payers agree to fund treatment, (b) industry generate effective treatments, (c) clinicians are prepared to prescribe treatments, and (d) patients are prepared to take treatments. The evidence base does not currently exist. SOPHIA will deliver this evidence and the shared value analysis to drive this revolution in obesity care. ver más
31/05/2025
NUID UCD
17M€
Duración del proyecto: 60 meses Fecha Inicio: 2020-05-26
Fecha Fin: 2025-05-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2020-05-26
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
IMI2-2019-17-01: Optimising future obesity treatment
Cerrada hace 5 años
Presupuesto El presupuesto total del proyecto asciende a 17M€
Líder del proyecto
UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5